LRP1 Mediates Endocytosis Activity and Is a Potential Therapeutic Target in Osteoarthritis

Abstract

Osteoarthritis (OA) is a degenerative disease characterized by cartilage abrasion and pain, affecting millions globally. However, current treatments focus on symptom management rather than modifying disease development. Recent studies have indicated that low-density lipoprotein receptor-related protein 1 (LRP1) is associated with maintaining cartilage homeostasis through its involvement in endocytosis and signaling pathways. LRP1 facilitates the removal of extracellular matrix (ECM)-degrading enzymes, including a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTSs) and matrix metalloproteinases (MMPs), thereby protecting against excessive cartilage breakdown. However, OA cartilage shows increased shedding of LRP1, leading to reduced endocytic capacity and elevated levels of these enzymes, contributing to accelerated ECM breakdown. LRP1 is also involved in key signaling pathways, such as Wnt/β-catenin, transforming growth factor-beta (TGF-β), and nuclear factor-kappa B (NF-κB), which regulate processes like chondrocyte proliferation, apoptosis, differentiation, and autophagy. Dysregulation of these pathways, combined with impaired LRP1-mediated endocytosis, fosters a catabolic environment in osteoarthritic cartilage. Emerging therapies targeting LRP1, such as gene interventions, exosome-based therapies, and small-molecule modulators, show potential in restoring LRP1 function, reducing cartilage degradation, and promoting joint repair. This review emphasizes the significance of LRP1 in the development of OA and explores its potential as a therapeutic target for creating disease-modifying strategies to maintain joint integrity and enhance patient well-being.

Keywords

endocytosis / low-density lipoprotein receptor-related protein 1 / osteoarthritis / therapeutic target

References

[1] R. Barnett, “Osteoarthritis,” Lancet 391, no. 10134 (2018): 1985.

[2] J. Martel-Pelletier, A. J. Barr, F. M. Cicuttini, et al., “Osteoarthritis,” Nature Reviews. Disease Primers 2 (2016): 16072.

[3] Y. Wu, J. Li, Y. Zeng, et al., “Exosomes Rewire the Cartilage Microenvironment in Osteoarthritis: From Intercellular Communication to Therapeutic Strategies,” International Journal of Oral Science 14, no. 1 (2022): 40.

[4] F. C. Grandi and N. Bhutani, “Epigenetic Therapies for Osteoarthritis,” Trends in Pharmacological Sciences 41, no. 8 (2020): 557-569.

[5] R. F. Loeser, J. A. Collins, and B. O. Diekman, “Ageing and the Pathogenesis of Osteoarthritis,” Nature Reviews Rheumatology 12, no. 7 (2016): 412-420.

[6] A. M. Valdes and M. B. Goldring, “Mitochondrial DNA Haplogroups and Ageing Mechanisms in Osteoarthritis,” Annals of the Rheumatic Diseases 76, no. 6 (2017): 939-941.

[7] O. H. Jeon, N. David, J. Campisi, and J. H. Elisseeff, “Senescent Cells and Osteoarthritis: A Painful Connection,” Journal of Clinical Investigation 128, no. 4 (2018): 1229-1237.

[8] H. Zhang, Y. Shao, Z. Yao, et al., “Mechanical Overloading Promotes Chondrocyte Senescence and Osteoarthritis Development Through Downregulating FBXW7,” Annals of the Rheumatic Diseases 81, no. 5 (2022): 676-686.

[9] I. Tachmazidou, K. Hatzikotoulas, L. Southam, et al., “Identification of New Therapeutic Targets for Osteoarthritis Through Genome-Wide Analyses of UK Biobank Data,” Nature Genetics 51, no. 2 (2019): 230-236, https://doi.org/10.1038/s41588-018-0327-1.

[10] E. Zengini, K. Hatzikotoulas, I. Tachmazidou, et al., “Genome-Wide Analyses Using UK Biobank Data Provide Insights Into the Genetic Architecture of Osteoarthritis,” Nature Genetics 50, no. 4 (2018): 549-558.

[11] A. Mobasheri, M. P. Rayman, O. Gualillo, J. Sellam, P. van der Kraan, and U. Fearon, “The Role of Metabolism in the Pathogenesis of Osteoarthritis,” Nature Reviews Rheumatology 13, no. 5 (2017): 302-311.

[12] W. S. Choi, G. Lee, W. H. Song, et al., “The CH25H-CYP7B1-RORalpha Axis of Cholesterol Metabolism Regulates Osteoarthritis,” Nature 566, no. 7743 (2019): 254-258.

[13] A. Mahmoudian, L. S. Lohmander, A. Mobasheri, M. Englund, and F. P. Luyten, “Early-Stage Symptomatic Osteoarthritis of the Knee - Time for Action,” Nature Reviews Rheumatology 17, no. 10 (2021): 621-632.

[14] P. G. Conaghan, A. D. Cook, J. A. Hamilton, and P. P. Tak, “Therapeutic Options for Targeting Inflammatory Osteoarthritis Pain,” Nature Reviews Rheumatology 15, no. 6 (2019): 355-363.

[15] J. N. Rauch, G. Luna, E. Guzman, et al., “LRP1 Is a Master Regulator of Tau Uptake and Spread,” Nature 580, no. 7803 (2020): 381-385.

[16] L. Liu, J. Henry, Y. Liu, et al., “LRP1 Repression by SNAIL Results in ECM Remodeling in Genetic Risk for Vascular Diseases,” Circulation Research 135, no. 11 (2024): 1084-1097, https://doi.org/10.1161/CIRCRESAHA.124.325269.

[17] Z. He, G. Wang, J. Wu, Z. Tang, and M. Luo, “The Molecular Mechanism of LRP1 in Physiological Vascular Homeostasis and Signal Transduction Pathways,” Biomedicine & Pharmacotherapy 139 (2021): 111667.

[18] K. Yamamoto, S. D. Scilabra, S. Bonelli, et al., “Novel Insights Into the Multifaceted and Tissue-Specific Roles of the Endocytic Receptor LRP1,” Journal of Biological Chemistry 300, no. 8 (2024): 107521.

[19] T. Yamamoto, C. G. Davis, M. S. Brown, et al., “The Human LDL Receptor: A Cysteine-Rich Protein With Multiple Alu Sequences in Its mRNA,” Cell 39, no. 1 (1984): 27-38.

[20] S. Takahashi, Y. Kawarabayasi, T. Nakai, J. Sakai, and T. Yamamoto, “Rabbit Very Low Density Lipoprotein Receptor: A Low Density Lipoprotein Receptor-Like Protein With Distinct Ligand Specificity,” Proceedings of the National Academy of Sciences of the United States of America 89, no. 19 (1992): 9252-9256.

[21] J. Herz, U. Hamann, S. Rogne, O. Myklebost, H. Gausepohl, and K. K. Stanley, “Surface Location and High Affinity for Calcium of a 500-Kd Liver Membrane Protein Closely Related to the LDL-Receptor Suggest a Physiological Role as Lipoprotein Receptor,” EMBO Journal 7, no. 13 (1988): 4119-4127.

[22] E. E. Bres and A. Faissner, “Low Density Receptor-Related Protein 1 Interactions With the Extracellular Matrix: More Than Meets the Eye,” Frontiers in Cell and Development Biology 7 (2019): 31.

[23] D. T. Au, A. L. Arai, W. E. Fondrie, S. C. Muratoglu, and D. K. Strickland, “Role of the LDL Receptor-Related Protein 1 in Regulating Protease Activity and Signaling Pathways in the Vasculature,” Current Drug Targets 19, no. 11 (2018): 1276-1288.

[24] L. Yang, C. C. Liu, H. Zheng, et al., “LRP1 Modulates the Microglial Immune Response via Regulation of JNK and NF-kappaB Signaling Pathways,” Journal of Neuroinflammation 13, no. 1 (2016): 304.

[25] H. Oue, Y. Yamazaki, W. Qiao, et al., “LRP1 in Vascular Mural Cells Modulates Cerebrovascular Integrity and Function in the Presence of APOE4,” JCI Insight 8, no. 7 (2023): 163822.

[26] W. Li, C. Chen, B. Xu, et al., “The LDL Receptor-Related Protein 1: Mechanisms and Roles in Promoting Abeta Efflux Transporter in Alzheimer's Disease,” Biochemical Pharmacology 231 (2024): 116643.

[27] H. W. Walling, L. J. Raggatt, D. W. Irvine, et al., “Impairment of the Collagenase-3 Endocytotic Receptor System in Cells From Patients With Osteoarthritis,” Osteoarthritis and Cartilage 11, no. 12 (2003): 854-863.

[28] K. Kawata, T. Eguchi, S. Kubota, et al., “Possible Role of LRP1, a CCN2 Receptor, in Chondrocytes,” Biochemical and Biophysical Research Communications 345, no. 2 (2006): 552-559.

[29] L. J. Raggatt, S. C. Jefcoat, I. Choudhury, S. Williams, M. Tiku, and N. C. Partridge, “Matrix Metalloproteinase-13 Influences ERK Signalling in Articular Rabbit Chondrocytes,” Osteoarthritis and Cartilage 14, no. 7 (2006): 680-689.

[30] N. Brandl, A. Zemann, I. Kaupe, et al., “Signal Transduction and Metabolism in Chondrocytes Is Modulated by Lactoferrin,” Osteoarthritis and Cartilage 18, no. 1 (2010): 117-125.

[31] K. Kawata, S. Kubota, T. Eguchi, et al., “Role of the Low-Density Lipoprotein Receptor-Related Protein-1 in Regulation of Chondrocyte Differentiation,” Journal of Cellular Physiology 222, no. 1 (2010): 138-148.

[32] K. Kawata, S. Kubota, T. Eguchi, et al., “Role of LRP1 in Transport of CCN2 Protein in Chondrocytes,” Journal of Cell Science 125, no. Pt 12 (2012): 2965-2972.

[33] S. D. Scilabra, L. Troeberg, K. Yamamoto, et al., “Differential Regulation of Extracellular Tissue Inhibitor of Metalloproteinases-3 Levels by Cell Membrane-Bound and Shed Low Density Lipoprotein Receptor-Related Protein 1,” Journal of Biological Chemistry 288, no. 1 (2013): 332-342.

[34] D. J. Gorski, W. Xiao, J. Li, et al., “Deletion of ADAMTS5 Does Not Affect Aggrecan or Versican Degradation but Promotes Glucose Uptake and Proteoglycan Synthesis in Murine Adipose Derived Stromal Cells,” Matrix Biology: Journal of the International Society for Matrix Biology 47 (2015): 66-84.

[35] K. Yamamoto, L. Troeberg, S. D. Scilabra, et al., “LRP-1-Mediated Endocytosis Regulates Extracellular Activity of ADAMTS-5 in Articular Cartilage,” FASEB Journal 27, no. 2 (2013): 511-521.

[36] L. Troeberg, C. Lazenbatt, E. K. M. F. Anower, et al., “Sulfated Glycosaminoglycans Control the Extracellular Trafficking and the Activity of the Metalloprotease Inhibitor TIMP-3,” Chemistry & Biology 21, no. 10 (2014): 1300-1309, https://doi.org/10.1016/j.chembiol.2014.07.014.

[37] K. Yamamoto, K. Owen, A. E. Parker, et al., “Low Density Lipoprotein Receptor-Related Protein 1 (LRP1)-Mediated Endocytic Clearance of a Disintegrin and Metalloproteinase With Thrombospondin Motifs-4 (ADAMTS-4): Functional Differences of Non-Catalytic Domains of ADAMTS-4 and ADAMTS-5 in LRP1 Binding,” Journal of Biological Chemistry 289, no. 10 (2014): 6462-6474.

[38] K. Yamamoto, S. Santamaria, K. A. Botkjaer, et al., “Inhibition of Shedding of Low-Density Lipoprotein Receptor-Related Protein 1 Reverses Cartilage Matrix Degradation in Osteoarthritis,” Arthritis & Rhematology 69, no. 6 (2017): 1246-1256.

[39] K. Yamamoto, C. Scavenius, M. M. Meschis, et al., “A Top-Down Approach to Uncover the Hidden Ligandome of Low-Density Lipoprotein Receptor-Related Protein 1 in Cartilage,” Matrix Biology: Journal of the International Society for Matrix Biology 112 (2022): 190-218.

[40] J. Fernandez-Torres, Y. Zamudio-Cuevas, A. Lopez-Reyes, et al., “Gene-Gene Interactions of the Wnt/Beta-Catenin Signaling Pathway in Knee Osteoarthritis,” Molecular Biology Reports 45, no. 5 (2018): 1089-1098.

[41] E. Yang, H. Zheng, H. Peng, and Y. Ding, “Lentivirus-Induced Knockdown of LRP1 Induces Osteoarthritic-Like Effects and Increases Susceptibility to Apoptosis in Chondrocytes via the Nuclear Factor-kappaB Pathway,” Experimental and Therapeutic Medicine 10, no. 1 (2015): 97-105.

[42] Y. Hu, Y. Liu, D. Lajeunesse, D. Mainard, J. Y. Jouzeau, and P. Reboul, “Identification of Two Populations of Osteoarthritic Osteoblasts According to the 1,25[OH](2) Vitamin D(3) Potency to Stimulate Osteocalcin,” Bio-Medical Materials and Engineering 25, no. 1 Suppl (2015): 103-110.

[43] S. C. Muratoglu, I. Mikhailenko, C. Newton, M. Migliorini, and D. K. Strickland, “Low Density Lipoprotein Receptor-Related Protein 1 (LRP1) Forms a Signaling Complex With Platelet-Derived Growth Factor Receptor-Beta in Endosomes and Regulates Activation of the MAPK Pathway,” Journal of Biological Chemistry 285, no. 19 (2010): 14308-14317.

[44] X. Pi, C. E. Schmitt, L. Xie, et al., “LRP1-Dependent Endocytic Mechanism Governs the Signaling Output of the Bmp System in Endothelial Cells and in Angiogenesis,” Circulation Research 111, no. 5 (2012): 564-574.

[45] J. Qu, S. Fourman, M. Fitzgerald, et al., “Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) is a Novel Receptor for Apolipoprotein A4 (APOA4) in Adipose Tissue,” Scientific Reports 11, no. 1 (2021): 13289.

[46] O. Sizova, L. S. John, Q. Ma, and J. J. Molldrem, “Multi-Faceted Role of LRP1 in the Immune System,” Frontiers in Immunology 14 (2023): 1166189.

[47] H. Jeon, W. Meng, J. Takagi, M. J. Eck, T. A. Springer, and S. C. Blacklow, “Implications for Familial Hypercholesterolemia From the Structure of the LDL Receptor YWTD-EGF Domain Pair,” Nature Structural Biology 8, no. 6 (2001): 499-504.

[48] Y. Zhao, D. Li, J. Zhao, J. Song, and Y. Zhao, “The Role of the Low-Density Lipoprotein Receptor-Related Protein 1 (LRP-1) in Regulating Blood-Brain Barrier Integrity,” Reviews in the Neurosciences 27, no. 6 (2016): 623-634.

[49] Y. Li, M. P. Marzolo, P. van Kerkhof, G. J. Strous, and G. Bu, “The YXXL Motif, but Not the Two NPXY Motifs, Serves as the Dominant Endocytosis Signal for Low Density Lipoprotein Receptor-Related Protein,” Journal of Biological Chemistry 275, no. 22 (2000): 17187-17194.

[50] H. Emonard, L. Theret, A. H. Bennasroune, and S. Dedieu, “Regulation of LRP-1 Expression: Make the Point,” Pathol Biol (Paris) 62, no. 2 (2014): 84-90.

[51] B. Van Gool, S. Dedieu, H. Emonard, and A. J. Roebroek, “The Matricellular Receptor LRP1 Forms an Interface for Signaling and Endocytosis in Modulation of the Extracellular Tumor Environment,” Frontiers in Pharmacology 6 (2015): 271.

[52] E. Laudati, A. S. Gilder, M. S. Lam, et al., “The Activities of LDL Receptor-Related Protein-1 (LRP1) Compartmentalize Into Distinct Plasma Membrane Microdomains,” Molecular and Cellular Neurosciences 76 (2016): 42-51.

[53] Y. Ding, X. Xian, W. L. Holland, S. Tsai, and J. Herz, “Low-Density Lipoprotein Receptor-Related Protein-1 Protects Against Hepatic Insulin Resistance and Hepatic Steatosis,” eBioMedicine 7 (2016): 135-145.

[54] J. Lee, H. Lee, H. Lee, et al., “ANKS1A Regulates LDL Receptor-Related Protein 1 (LRP1)-Mediated Cerebrovascular Clearance in Brain Endothelial Cells,” Nature Communications 14, no. 1 (2023): 8463.

[55] H. M. Ismail, K. Yamamoto, T. L. Vincent, H. Nagase, L. Troeberg, and J. Saklatvala, “Interleukin-1 Acts via the JNK-2 Signaling Pathway to Induce Aggrecan Degradation by Human Chondrocytes,” Arthritis & Rhematology 67, no. 7 (2015): 1826-1836.

[56] C. M. Doherty, R. Visse, D. Dinakarpandian, D. K. Strickland, H. Nagase, and L. Troeberg, “Engineered Tissue Inhibitor of Metalloproteinases-3 Variants Resistant to Endocytosis Have Prolonged Chondroprotective Activity,” Journal of Biological Chemistry 291, no. 42 (2016): 22160-22172.

[57] K. Yamamoto, H. Okano, W. Miyagawa, et al., “MMP-13 Is Constitutively Produced in Human Chondrocytes and Co-Endocytosed With ADAMTS-5 and TIMP-3 by the Endocytic Receptor LRP1,” Matrix Biology: Journal of the International Society for Matrix Biology 56 (2016): 57-73.

[58] A. Chanalaris, C. Doherty, B. D. Marsden, et al., “Suramin Inhibits Osteoarthritic Cartilage Degradation by Increasing Extracellular Levels of Chondroprotective Tissue Inhibitor of Metalloproteinases 3,” Molecular Pharmacology 92, no. 4 (2017): 459-468.

[59] S. Santamaria, O. Fedorov, J. McCafferty, et al., “Development of a Monoclonal Anti-ADAMTS-5 Antibody That Specifically Blocks the Interaction With LRP1,” MAbs 9, no. 4 (2017): 595-602.

[60] Z. Peng, H. Sun, V. Bunpetch, et al., “The Regulation of Cartilage Extracellular Matrix Homeostasis in Joint Cartilage Degeneration and Regeneration,” Biomaterials 268 (2021): 120555.

[61] Q. Deng, X. Yu, S. Deng, et al., “Midkine Promotes Articular Chondrocyte Proliferation Through the MK-LRP1-Nucleolin Signaling Pathway,” Cellular Signalling 65 (2020): 109423.

[62] Q. Hu and M. Ecker, “Overview of MMP-13 as a Promising Target for the Treatment of Osteoarthritis,” International Journal of Molecular Sciences 22, no. 4 (2021): 1742.

[63] A. Mukherjee and B. Das, “The Role of Inflammatory Mediators and Matrix Metalloproteinases (MMPs) in the Progression of Osteoarthritis,” Biomaterials and Biosystems 13 (2024): 100090.

[64] D. J. Wilkinson, H. Wang, A. Habgood, et al., “Matriptase Induction of Metalloproteinase-Dependent Aggrecanolysis In Vitro and In Vivo: Promotion of Osteoarthritic Cartilage Damage by Multiple Mechanisms,” Arthritis & Rhematology 69, no. 8 (2017): 1601-1611.

[65] T. Li, J. Peng, Q. Li, Y. Shu, P. Zhu, and L. Hao, “The Mechanism and Role of ADAMTS Protein Family in Osteoarthritis,” Biomolecules 12, no. 7 (2022): 959.

[66] Z. Wang, W. Shi, L. Wu, et al., “TMF Inhibits Extracellular Matrix Degradation by Regulating the C/EBPbeta/ADAMTS5 Signaling Pathway in Osteoarthritis,” Biomedicine & Pharmacotherapy 174 (2024): 116501.

[67] L. Jiang, J. Lin, S. Zhao, et al., “ADAMTS5 in Osteoarthritis: Biological Functions, Regulatory Network, and Potential Targeting Therapies,” Frontiers in Molecular Biosciences 8 (2021): 703110.

[68] A. R. Bihlet, I. Byrjalsen, K. Mundbjerg, et al., “A Phase 2b Double-Blind Placebo-Controlled Randomized Clinical Trial of SB-061, an Aggrecan Mimetic, in Patients With Symptomatic Knee Osteoarthritis,” Osteoarthritis and Cartilage 32, no. 11 (2024): 1471-1480.

[69] C. R. Coveney, I. Collins, M. Mc Fie, A. Chanalaris, K. Yamamoto, and A. K. T. Wann, “Cilia Protein IFT88 Regulates Extracellular Protease Activity by Optimizing LRP-1-Mediated Endocytosis,” FASEB Journal 32, no. 12 (2018): fj201800334.

[70] T. Karila, T. Tervahartiala, B. Cohen, and T. Sorsa, “The Collagenases: Are They Tractable Targets for Preventing Cartilage Destruction in Osteoarthritis?,” Expert Opinion on Therapeutic Targets 26, no. 2 (2022): 93-105.

[71] H. S. Roy, G. Dubey, V. K. Sharma, P. V. Bharatam, and D. Ghosh, “Molecular Docking and Molecular Dynamics to Identify Collagenase Inhibitors as Lead Compounds to Address Osteoarthritis,” Journal of Biomolecular Structure & Dynamics 40, no. 5 (2022): 2339-2351.

[72] S. Wang, P. Meng, L. Yuan, and X. Guo, “Analysis of N-Glycosylation Protein of Kashin-Beck Disease Chondrocytes Derived From Induced Pluripotent Stem Cells Based on Label-Free Strategies With LC-MS/MS,” Molecular Omics 19, no. 6 (2023): 454-463.

[73] W. Lu, Z. He, J. Shi, et al., “AMD3100 Attenuates Post-Traumatic Osteoarthritis by Maintaining Transforming Growth Factor-beta1-Induced Expression of Tissue Inhibitor of Metalloproteinase-3 via the Phosphatidylinositol 3-Kinase/Akt Pathway,” Frontiers in Pharmacology 10 (2019): 1554.

[74] J. Green, R. A. J. Tinson, J. H. J. Betts, et al., “Suramin Analogues Protect Cartilage Against Osteoarthritic Breakdown by Increasing Levels of Tissue Inhibitor of Metalloproteinases 3 (TIMP-3) in the Tissue,” Bioorganic & Medicinal Chemistry 92 (2023): 117424.

[75] F. Liu, L. Li, W. Lu, et al., “Scutellarin Ameliorates Cartilage Degeneration in Osteoarthritis by Inhibiting the Wnt/Beta-Catenin and MAPK Signaling Pathways,” International Immunopharmacology 78 (2020): 105954.

[76] Q. Shi, L. Huang, J. Duan, G. Kuang, M. Lu, and X. Tan, “The Effects of Jiawei Duhuo Jisheng Mixture on Wnt/Beta-Catenin Signaling Pathway in the Synovium Inflamed by Knee Osteoarthritis: An In Vitro and In Vivo Experiment,” Journal of Ethnopharmacology 294 (2022): 115363.

[77] Y. Huang, L. Jiang, H. Yang, et al., “Variations of Wnt/Beta-Catenin Pathway-Related Genes in Susceptibility to Knee Osteoarthritis: A Three-Centre Case-Control Study,” Journal of Cellular and Molecular Medicine 23, no. 12 (2019): 8246-8257.

[78] E. P. Dennis, S. M. Edwards, R. M. Jackson, et al., “CRELD2 Is a Novel LRP1 Chaperone That Regulates Noncanonical WNT Signaling in Skeletal Development,” Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research 35, no. 8 (2020): 1452-1469.

[79] R. K. Zhang, L. K. Yang, L. J. Huang, Q. Zhao, and D. Z. Cai, “Expression of Lipoprotein Related Genes in Subchondral Bone of Early Experimental Osteoarthritis,” Zhongguo Gu Shang 27, no. 1 (2014): 54-57.

[80] W. Yan, L. Zheng, X. Xu, et al., “Heterozygous LRP1 Deficiency Causes Developmental Dysplasia of the Hip by Impairing Triradiate Chondrocytes Differentiation due to Inhibition of Autophagy,” Proceedings of the National Academy of Sciences of the United States of America 119, no. 37 (2022): e2203557119.

[81] W. C. Chen, Y. C. Lu, S. J. Kuo, et al., “Resistin Enhances Il-1beta and Tnf-Alpha Expression in Human Osteoarthritis Synovial Fibroblasts by Inhibiting Mir-149 Expression via the Mek and Erk Pathways,” FASEB Journal 34, no. 10 (2020): 13671-13684.

[82] Y. N. Pan, C. Jia, J. P. Yu, Z. W. Wu, G. C. Xu, and Y. X. Huang, “Fibroblast Growth Factor 9 Reduces TBHP-Induced Oxidative Stress in Chondrocytes and Diminishes Mouse Osteoarthritis by Activating ERK/Nrf2 Signaling Pathway,” International Immunopharmacology 114 (2023): 109606.

[83] T. Feng and Q. F. Wu, “A Review of Non-Coding RNA Related to NF-kappaB Signaling Pathway in the Pathogenesis of Osteoarthritis,” International Immunopharmacology 106 (2022): 108607.

[84] Q. Guo, X. Chen, J. Chen, et al., “STING Promotes Senescence, Apoptosis, and Extracellular Matrix Degradation in Osteoarthritis via the NF-Kappab Signaling Pathway,” Cell Death & Disease 12, no. 1 (2021): 13.

[85] J. He, W. Cao, I. Azeem, and Z. Shao, “Epigenetics of Osteoarthritis: Histones and TGF-beta1,” Clinica Chimica Acta 510 (2020): 593-598.

[86] Z. Deng, F. Chen, Y. Liu, et al., “Losartan Protects Against Osteoarthritis by Repressing the TGF-beta1 Signaling Pathway via Upregulation of PPARgamma,” Journal of Orthopaedic Translation 29 (2021): 30-41.

[87] S. H. Ping, F. M. Tian, H. Liu, et al., “Raloxifene Inhibits the Overexpression of TGF-beta1 in Cartilage and Regulates the Metabolism of Subchondral Bone in Rats With Osteoporotic Osteoarthritis,” Bosnian Journal of Basic Medical Sciences 21, no. 3 (2021): 284-293.

[88] D. M. Sumsuzzman, J. Choi, Z. A. Khan, G. Kamenos, and Y. Hong, “Melatonin Maintains Anabolic-Catabolic Equilibrium and Regulates Circadian Rhythm During Osteoarthritis Development in Animal Models: A Systematic Review and Meta-Analysis,” Frontiers in Pharmacology 12 (2021): 714974.

[89] S. Li, R. Shao, S. Li, et al., “A Monoallelic Variant in CCN2 Causes an Autosomal Dominant Spondyloepimetaphyseal Dysplasia With Low Bone Mass,” Bone Research 12, no. 1 (2024): 60.

[90] T. Nishida and S. Kubota, “Roles of CCN2 as a Mechano-Sensing Regulator of Chondrocyte Differentiation,” Japanese Dental Science Review 56, no. 1 (2020): 119-126.

[91] G. Wang, X. Zhang, J. Xu, et al., “The Role of Mitochondrial Autophagy in Osteoarthritis,” iScience 27, no. 9 (2024): 110741.

[92] J. Wang, Y. Zhang, J. Cao, et al., “The Role of Autophagy in Bone Metabolism and Clinical Significance,” Autophagy 19, no. 9 (2023): 2409-2427.

[93] D. Szala, M. Kopanska, J. Trojniak, et al., “The Role of MicroRNAs in the Pathophysiology of Osteoarthritis,” International Journal of Molecular Sciences 25, no. 12 (2024): 6352.

[94] J. Wu, J. Wu, W. Xiang, et al., “Engineering Exosomes Derived From TNF-Alpha Preconditioned IPFP-MSCs Enhance Both Yield and Therapeutic Efficacy for Osteoarthritis,” Journal of Nanobiotechnology 22, no. 1 (2024): 555.

[95] K. Lu, Q. Wang, L. Hao, et al., “miR-204 Ameliorates Osteoarthritis Pain by Inhibiting SP1-LRP1 Signaling and Blocking Neuro-Cartilage Interaction,” Bioactive Materials 26 (2023): 425-436.

[96] Y. Lyu, H. Deng, C. Qu, et al., “Identification of Proteins and N-Glycosylation Sites of Knee Cartilage in Kashin-Beck Disease Compared With Osteoarthritis,” International Journal of Biological Macromolecules 210 (2022): 128-138.

[97] S. Esmail and M. F. Manolson, “Advances in Understanding N-Glycosylation Structure, Function, and Regulation in Health and Disease,” European Journal of Cell Biology 100, no. 7-8 (2021): 151186.

[98] C. Pasala, S. Sharma, T. Roychowdhury, E. Moroni, G. Colombo, and G. Chiosis, “N-Glycosylation as a Modulator of Protein Conformation and Assembly in Disease,” Biomolecules 14, no. 3 (2024): 282.

[99] G. N. Alzhrani, S. T. Alanazi, S. Y. Alsharif, et al., “Exosomes: Isolation, Characterization, and Biomedical Applications,” Cell Biology International 45, no. 9 (2021): 1807-1831.

[100] Y. Jin, M. Xu, H. Zhu, et al., “Therapeutic Effects of Bone Marrow Mesenchymal Stem Cells-Derived Exosomes on Osteoarthritis,” Journal of Cellular and Molecular Medicine 25, no. 19 (2021): 9281-9294.

[101] E. Mianehsaz, H. R. Mirzaei, M. Mahjoubin-Tehran, et al., “Mesenchymal Stem Cell-Derived Exosomes: A New Therapeutic Approach to Osteoarthritis?,” Stem Cell Research & Therapy 10, no. 1 (2019): 340.

[102] Y. Hu, X. Chen, S. Wang, Y. Jing, and J. Su, “Subchondral Bone Microenvironment in Osteoarthritis and Pain,” Bone Research 9, no. 1 (2021): 20.

[103] W. Hu, Y. Chen, C. Dou, and S. Dong, “Microenvironment in Subchondral Bone: Predominant Regulator for the Treatment of Osteoarthritis,” Annals of the Rheumatic Diseases 80, no. 4 (2021): 413-422.

[104] J. Peixoto, C. Principe, A. Pestana, et al., “Using a Dual CRISPR/Cas9 Approach to Gain Insight Into the Role of LRP1B in Glioblastoma,” International Journal of Molecular Sciences 24, no. 14 (2023): 11285.

[105] H. Tang, X. Zhao, and X. Jiang, “Synthetic Multi-Layer Nanoparticles for CRISPR-Cas9 Genome Editing,” Advanced Drug Delivery Reviews 168 (2021): 55-78.

[106] Y. Jeong, L. Deveza, L. Ortinau, K. Lei, J. R. Dawson, and D. Park, “Identification of LRP1+CD13+ Human Periosteal Stem Cells That Require LRP1 for Bone Repair,” JCI Insight 9, no. 22 (2024): e173831.

[107] S. Tang, L. Yao, J. Ruan, et al., “Single-Cell Atlas of Human Infrapatellar Fat Pad and Synovium Implicates APOE Signaling in Osteoarthritis Pathology,” Science Translational Medicine 16, no. 731 (2024): eadf4590.

RIGHTS & PERMISSIONS

2025 The Author(s). Orthopaedic Surgery published by Tianjin Hospital and John Wiley & Sons Australia, Ltd.